Table 4.
Prevalence [n (%)] of ID among anaemic patients by CKD stage
| CKD Stages 1–2 | CKD Stage 3 | CKD Stages 4–5 | Total | P-value | |
|---|---|---|---|---|---|
| na | (n = 41) | (n = 50) | (n = 81) | (n = 172) | |
| Hb < 10 g/dL | 1 (2.4) | 1 (2.0) | 7 (8.6) | 9 (5.2) | 0.245 |
| Hb < 11 g/dL | 5 (12.2) | 6 (12.0) | 21 (25.9) | 32 (18.6) | 0.073 |
| Hb < 12 g/dL | 8 (19.5) | 9 (18.0) | 27 (33.3) | 44 (25.6) | 0.097 |
| WHO definitionb | 10 (24.4) | 13 (26.0) | 29 (35.8) | 52 (30.2) | 0.344 |
| Totalc | 19 (46.3) | 23 (45.1) | 38 (45.2) | 80 (45.5) | 1.000 |
a
Number of patients with available Hb, iron studies and eGFR.
b
WHO criteria: Hb < 13 g/dL for men and < 12 g/dL for women.
c
Irrespective of anaemia status.